首页> 美国卫生研究院文献>Technology in Cancer Research Treatment >A Comparison of Different Prophylactic Intravesical Chemotherapy Regimens forBladder Cancer Recurrence After Nephroureterectomy for Primary Upper Tract UrothelialCarcinomas: A Retrospective 2-center Study
【2h】

A Comparison of Different Prophylactic Intravesical Chemotherapy Regimens forBladder Cancer Recurrence After Nephroureterectomy for Primary Upper Tract UrothelialCarcinomas: A Retrospective 2-center Study

机译:不同预防性膀胱内化疗方案的比较。肾癌切除术后原发性上段尿道膀胱癌的膀胱癌复发癌:回顾性2中心研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Prophylactic intravesical chemotherapy can decrease bladder cancer recurrence rate after nephroureterectomy for upper tract urothelial carcinoma. We aimed to compare the effect of different prophylactic intravesical chemotherapy regimens in bladder recurrence-free survival. From 2000 to 2016, a total of 270 patients treated with radical nephroureterectomy at both institutions were enrolled. Patients were divided into 3 groups: multiple-instillation group, single-instillation group, and no-instillation group. Univariable and multivariable analyses with Cox regression methods were performed to calculate hazard ratios for bladder recurrence using clinicopathologic data, including our different instillation strategies. Sixty-three (23.3%) of 270 patients had subsequent intravesical recurrence. Significantly fewer patients in both the instillation groups had a recurrence compared to in the no-instillation group (13.1% vs 25.4% vs 41.5%, P = .001). Furthermore, there was a significant difference between both the instillation groups (P = .016). In different subsets of patients with upper tract urothelial carcinoma, intravesical chemotherapy, either multiple or single instillation, was a protective factor of bladder recurrence in pT2-4 (P = .002) and high grade (P < .0001). Importantly, Kaplan-Meier curves of bladder recurrence-free survival rate were increased observably in multiple-instillationgroup compared to that in single-instillation group (P = .053 in pT2-4subgroup; P = .048 in high-grade subgroup, respectively). Onmultivariable analysis, intravesical chemotherapy (P < .001),especially multiple instillations (hazard ratio 0.230; 95% confidence interval0.110-0.479), was identified an independent predictor of bladder recurrence-free survival.In conclusion, prophylactic intravesical chemotherapy effectively prevents bladderrecurrence after nephroureterectomy, especially with multiple instillations, in patientswith invasive upper tract urothelial carcinoma or at high-grade status.
机译:预防性膀胱内化疗可降低上尿路尿路上皮癌肾癌切除术后膀胱癌的复发率。我们旨在比较不同的预防性膀胱内化疗方案在无膀胱复发生存中的作用。从2000年到2016年,这两家机构的270名患者接受了根治性肾切除术治疗。将患者分为三组:多次滴注组,单次滴注组和不滴注组。使用Cox回归方法进行单变量和多变量分析,以使用临床病理数据(包括我们的不同滴注策略)来计算膀胱复发的危险比。 270例患者中有63例(23.3%)随后发生了膀胱内复发。与未滴注组相比,两个滴注组的复发患者均明显减少(13.1%vs 25.4%vs 41.5%,P = .001)。此外,两个滴注组之间存在显着差异(P = .016)。在上段尿路上皮癌患者的不同亚组中,多次或单次滴注膀胱内化疗是pT2-4(P = .002)和高级别(P <.0001)膀胱复发的保护因素。重要的是,在多次滴注中,膀胱无复发生存率的Kaplan-Meier曲线明显增加与单滴组比较(pT2-4中P = .053)亚组分别在高级小组中P = .048)。上多变量分析,膀胱内化疗(P <.001),尤其是多次滴注(危险比0.230; 95%置信区间(0.110-0.479)被确定为膀胱无复发生存的独立预测因子。总之,预防性膀胱内化疗有效地预防了膀胱肾输尿管切除术后复发的患者,尤其是多次滴注的患者患有浸润性上尿路上皮癌或处于高度状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号